The Novo Nordisk Foundation (NNF) and Cleveland Clinic have launched a groundbreaking fellowship program to integrate quantum technologies and artificial intelligence (AI) into biomedical research and patient care. The Cleveland Clinic – Denmark: Quantum-AI Biomedical Frontiers Fellowship Program aims to enhance medical science and healthcare applications. Over the next three years, NNF will grant up to $6.2 million to support the exchange of 12 researchers between Cleveland Clinic and Denmark.
Each fellow will have a three-year term to conduct high-level research at either institution. The collaboration is designed to enable the use of advanced critical technologies, such as quantum technology and AI, in biomedical research and practical clinical applications, ensuring these innovative technologies contribute to the understanding of diseases and improving patient outcomes,” said Lene Oddershede, Senior Vice President, Head of Natural and Technical Sciences at Novo Nordisk Foundation. The program focuses on key scientific areas, including enhanced diagnostic precision, innovative drug discovery, optimization of clinical trials, and personalized medicine development.
Biomedical fellowship enhances medical innovation
Fellows can collaborate with IBM researchers and Cleveland Clinic scientists through the Discovery Accelerator partnership. This fellowship is a testament to the power of collaboration between Cleveland Clinic and the Novo Nordisk Foundation,” said Lara Jehi, MD, Chief Research Information Officer at Cleveland Clinic.
By combining our strengths, we aim to accelerate the translation of quantum technologies and artificial intelligence into clinical settings, fostering a new era of medical innovation.
The program encourages applicants to consider industrial placements with leading technology companies and startups lasting three to six months. These placements aim to provide practical experience and foster the translation of research innovations into market-ready medical solutions. “We invite forward-thinking clinician scientists and post-doctoral researchers to apply for this unique opportunity,” said Martin Ridderstråle, SVP and Head of Medical Science at NNF.
The application process will be rigorously managed by the NNF’s Committee on Interdisciplinary Research in collaboration with Cleveland Clinic, ensuring a thorough and meritocratic selection process.
Early-stage researchers interested in becoming leaders at the intersection of quantum technologies, AI, and medicine are encouraged to visit the NNF webpage for more details about the application process.
